Welcome to our dedicated page for PRF Technologies news (Ticker: PRFX), a resource for investors and traders seeking the latest updates and insights on PRF Technologies stock.
PRF Technologies Ltd. reports developments across clinical-stage specialty pharmaceuticals and AI-driven solar analytics. The company focuses on reformulating established therapeutics for post-operative pain management and, through majority-owned LayerBio, is developing OcuRing™-K, a bio-erodible intraocular ring designed to deliver ketorolac for post-cataract pain and inflammation.
PRF news also covers the company’s DeepSolar business unit, which develops AI-driven digital asset management, forecasting, performance monitoring, and technical due diligence tools for utility-scale solar plants. Recurring updates include ocular drug-delivery regulatory milestones, preclinical and clinical safety data, patent activity, SaaS deployments, commercial collaborations, capital actions, and governance changes.
PRF Technologies (Nasdaq: PRFX) is advancing its AI platform DeepSolar Predict toward planned commercial launch. The solution targets revenue optimization for solar, wind and battery storage by combining weather intelligence, AI forecasting, storage optimization and real-time market decision support.
The platform builds on DeepSolar’s NVIDIA Connect participation and a patent application for plant-level micro-climate modeling intended to improve solar production forecasts. Planned capabilities include localized weather modeling, production and portfolio forecasting, imbalance risk tools, battery storage orchestration and market-informed delivery planning across renewable asset portfolios.
PRF Technologies (Nasdaq:PRFX) reported positive preclinical data for its lead post-operative pain candidate PRF-110 in a head-to-head pig study versus approved benchmark ZYNRELEF. PRF-110 showed sustained, 72-hour analgesic activity comparable to ZYNRELEF using a ropivacaine-only, NSAID-free extended-release formulation.
According to PRF, both products reduced pain-related measures, PRF-110 maintained comparable efficacy at later timepoints, and safety and local tolerability were consistent with prior preclinical experience, with no unexpected findings. The company believes these results will support future development and regulatory strategy for PRF-110.
PRF Technologies (Nasdaq: PRFX) announced FDA clearance of its IND for OcuRing-K, a bio-erodible intraocular ring to deliver ketorolac as a single intraoperative application.
The clearance enables a U.S. multi-center Phase II trial with enrollment expected in the second half of 2026, evaluating pain, inflammation, and safety after cataract surgery.
PRF Technologies (Nasdaq: PRFX) reported a 2025 business update highlighting a majority investment in LayerBio and acquisition of DeepSolar, advancing healthcare and AI-driven solar platforms.
Key facts: Net loss $4.8M (2025 vs $14.6M in 2024), R&D $1.1M (2025 vs $11.7M), cash ~$4.1M and positive working capital ~$1.9M. DeepSolar secured a 71 MW SaaS agreement and filed a patent; LayerBio advanced OcuRing™-K with IND-supporting work and Phase I safety data showing no treatment-related serious adverse events.
PRF Technologies (Nasdaq: PRFX) announced a commercial collaboration with Blade Ranger on March 17, 2026 to accelerate deployment of its DeepSolar AI platform across utility-scale solar portfolios.
The agreement targets multiple enterprise engagements, each with a minimum scope of 150 MW, aiming to expand DeepSolar’s integration for forecasting, diagnostics and performance optimization with large operators and investors.
PRF Technologies (Nasdaq: PRFX) said its DeepSolar unit signed a commercial analytics services agreement with a special-purpose company of EDF Power Solutions Israel on Feb 18, 2026.
The engagement begins a technical due diligence (TDD) on an operating utility-scale solar plant in Israel using DeepSolar’s Smart TDD analytics to assess asset condition and performance and represents a new commercial revenue opportunity.
PRF Technologies (Nasdaq: PRFX) signed a commercial SaaS agreement to deploy its DeepSolar analytics platform at the 71 MW Satu Mare utility-scale solar plant in Romania with Shikun & Binui Energy.
The deployment delivers continuous performance monitoring, predictive analytics, and technical due diligence tools, builds on prior European activity, and is complemented by Smart TDD, DeepSolar Predict, and a patent application for micro-climate modeling.
PRF Technologies (Nasdaq: PRFX) filed a patent application for proprietary solar plant micro-climate forecast modeling aimed at improving short-term and intraday solar energy production forecasts.
The filing protects core IP behind DeepSolar Predict, a platform the company says adapts in real time to localized environmental dynamics. PRF also announced acceptance into the NVIDIA Connect Program. The company states improved forecasts could reduce imbalance penalties, enhance revenue capture in day-ahead and intraday markets, and support better operational decisions for utility-scale solar assets.
PainReform (Nasdaq: PRFX) reported that preclinical rabbit studies and a Phase I clinical study of the OcuRing™-K drop-less sustained-release ocular delivery platform showed a favorable safety profile on Jan 12, 2026. The Phase I trial in cataract surgery patients recorded no treatment-related adverse events, no serious adverse events, and proper device positioning in all treated eyes. Preclinical results showed no ocular tissue abnormalities and no meaningful differences versus control. PainReform and majority-owned LayerBio are advancing IND-enabling activities to support next-phase clinical evaluation in the United States.
PainReform (Nasdaq: PRFX) announced on January 5, 2026 that its DeepSolar unit launched Smart TDD, a lifecycle-wide solar Technical Due Diligence service targeting the global solar asset M&A market. Smart TDD combines 100% component and operational-history coverage, AI-driven analytics with physics-based modeling, expert engineering review, prioritized findings by financial impact, and preliminary results delivered within days. The release cites a large addressable market—$500 billion invested in 2024 and more than $60 billion of solar assets traded annually—and positions Smart TDD for use at commissioning, warranty expiry, underperformance remediation, and asset acquisitions.